Various research studies indicated that now lung cancer immunotherapeutic therapy aims to enhance the cytotoxological action of lymphocytes by restricting the activities of suppressor molecules such as cytotoxic T cell antigen 4 (CTLA-4) and programmed death-1 (PD-1) [59]. Here, PDCD1 is linked to lung carcinoma.